DiaMedica Therapeutics Secures $11.8 Million Investment to Advance Breakthrough Treatments

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a pioneering biopharmaceutical firm renowned for its innovative approach to severe ischemic diseases, has announced a significant milestone today. The company successfully finalized agreements for a private placement offering, securing $11.8 million in gross proceeds from accredited investors. This strategic funding round underscores DiaMedica’s commitment to advancing clinical and product…

Read More

Nuclera Secures $75 Million in Series C Financing to Transform Protein Discovery

In a significant boost for biotechnology innovation, Nuclera has successfully closed a $75 million financing round, aimed at advancing its groundbreaking eProtein Discovery platform. This Series C round was led by Elevage Medical Technologies and saw participation from various prominent investors, including Patient Square Capital, British Patient Capital, Cambridge Innovation Capital, and others. This substantial…

Read More

Clear Street Expands Equity Trading Capabilities with Acquisition of Fox River Algorithmic Trading Business from Instinet

Clear Street, a leading cloud-native financial technology firm dedicated to modernizing the brokerage ecosystem, has announced a strategic agreement to acquire Instinet’s Fox River algorithmic trading business. This acquisition marks a significant step for Clear Street in enhancing its electronic trading capabilities across US and Canadian equities, catering specifically to both buy-side and sell-side clients,…

Read More

Bio-Sourcing Secures €12.5M from EIC Accelerator to Revolutionize Biotherapeutic Production

In a remarkable advancement for sustainable biopharmaceuticals, Belgian company Bio-Sourcing has successfully secured €12.5 million from the European Innovation Council (EIC) Accelerator. This funding comprises €2.5 million in grants and €10 million in equity, aimed at enhancing the company’s innovative BioMilk platform, which is poised to redefine the production of biotherapeutics, particularly monoclonal antibodies. The…

Read More

Courier Health Secures $16.5 Million Investment to Revolutionize Patient Engagement in Life Sciences

Courier Health, a trailblazing technology firm dedicated to enhancing patient support within the life sciences sector, has announced a significant milestone with the closure of a $16.5 million Series A funding round. Led by Norwest Venture Partners and supported by existing investor Work-Bench, this financing underscores a pivotal moment for the company as it continues…

Read More

ZeroTier Secures $13.5 Million in Series A Funding, Appoints Industry Veteran Andrew Gault as CEO

ZeroTier, a pioneering company in virtual networking, has announced a successful $13.5 million Series A funding round, led by Battery Ventures. This investment also saw contributions from Bonfire Ventures, Anorak Ventures, Grand Enterprises B.V., Airbridge Equity Partners, First In Ventures, and 7percent Ventures. This fresh capital is set to bolster ZeroTier’s mission to simplify secure…

Read More

Transforming Event Experiences: EventCHI Secures €1.6M+ for AI and Blockchain Integration

In a bold move to redefine the landscape of global events, Rotterdam’s own EventCHI has successfully closed a substantial seed funding round, amassing over €1.6 million. This significant investment marks a pivotal moment for the innovative startup, poised to revolutionize event experiences through the seamless integration of artificial intelligence and blockchain technologies. Founded by visionaries…

Read More

Delta Data Unveils Enhanced Global Fee Management Solution

Delta Data, a leading provider of software solutions for the global mutual fund and pooled fund industry, has announced significant advancements to its Fee Management solution. These updates empower asset management firms to seamlessly manage intermediary fees across international jurisdictions, reinforcing Delta Data’s commitment to enhancing operational efficiency and global market accessibility. The enhanced functionality…

Read More

NephroDI Therapeutics Secures Strategic Investment to Propel Innovative Therapy for Pediatric Kidney Disease

NephroDI Therapeutics (NephroDI), a leading near-clinical stage pharmaceutical company specializing in kidney disorders, proudly announces a significant Series A investment from life sciences venture capital firm Sound Bioventures. This latest infusion of capital, in tandem with a previously established strategic corporate partnership, is set to advance the development of NDI-5001, a groundbreaking small molecule AMPK…

Read More